Emilia Scalzulli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML	CANCER	2023
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	LEUKEMIA & LYMPHOMA	2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study	FRONTIERS IN PHARMACOLOGY	2023
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib		2023
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	EXPERT REVIEW OF HEMATOLOGY	2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents	CURRENT CANCER DRUG TARGETS	2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions	CURRENT HEMATOLOGIC MALIGNANCY REPORTS	2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	CURRENT OPINION IN ONCOLOGY	2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort	BLOOD ADVANCES	2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	EXPERT REVIEW OF HEMATOLOGY	2022
Asciminib in chronic myeloid leukemia	DRUGS OF TODAY	2022
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	LEUKEMIA & LYMPHOMA	2022
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group	ANNALS OF HEMATOLOGY	2022
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide	BLOOD CANCER JOURNAL	2022
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation	JOURNAL OF CLINICAL MEDICINE	2022
Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases	BLOOD	2022
Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study	BLOOD	2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?	JOURNAL OF CLINICAL MEDICINE	2022
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021